Kangyuan Pharmaceutical: Received the clinical trial approval notice for the Jianpi Shugan Guben Granules.

Kangyuan Pharmaceutical announced that it has recently received the Drug Clinical Trial Approval Letter for the Spleen-Nourishing, Liver-Calming, and Constitution-Strengthening Granules issued by the National Medical Products Administration. This drug is a Class 1.1 innovative Chinese medicine, indicated for the treatment of liver-qi stagnation and spleen deficiency in patients with diarrhea-predominant irritable bowel syndrome. The company owns the independent and complete intellectual property rights of this new drug, with a total research and development investment of approximately 7.82 million yuan. The Spleen-Nourishing, Liver-Calming, and Constitution-Strengthening Granules have shown good therapeutic effects and safety in preclinical pharmacological studies. Currently, there are no drugs on the domestic market specifically for "spleen-nourishing, kidney-warming, liver-soothing, and qi-regulating," so it is expected that this drug will have good market prospects.